These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34078743)

  • 21. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.
    Raymond DD; Stewart SM; Lee J; Ferdman J; Bajic G; Do KT; Ernandes MJ; Suphaphiphat P; Settembre EC; Dormitzer PR; Del Giudice G; Finco O; Kang TH; Ippolito GC; Georgiou G; Kepler TB; Haynes BF; Moody MA; Liao HX; Schmidt AG; Harrison SC
    Nat Med; 2016 Dec; 22(12):1465-1469. PubMed ID: 27820604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans.
    Zost SJ; Lee J; Gumina ME; Parkhouse K; Henry C; Wu NC; Lee CD; Wilson IA; Wilson PC; Bloom JD; Hensley SE
    Cell Rep; 2019 Dec; 29(13):4460-4470.e8. PubMed ID: 31875553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.
    Smith G; Liu Y; Flyer D; Massare MJ; Zhou B; Patel N; Ellingsworth L; Lewis M; Cummings JF; Glenn G
    Vaccine; 2017 Sep; 35(40):5366-5372. PubMed ID: 28844407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.
    Christensen SR; Toulmin SA; Griesman T; Lamerato LE; Petrie JG; Martin ET; Monto AS; Hensley SE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
    Allen JD; Ross TM
    J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anamnestic broadly reactive antibodies induced by H7N9 virus more efficiently bind to seasonal H3N2 strains.
    Chen Y; Hilchey SP; Wang J; Garigen J; Zand MS; Huang J
    Hum Vaccin Immunother; 2022 Nov; 18(6):2128014. PubMed ID: 36197079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4.
    Schuele C; Schmeisser F; Orr M; Meseda CA; Vasudevan A; Wang W; Weiss CD; Woerner A; Atukorale VN; Pedro CL; Weir JP
    Influenza Other Respir Viruses; 2023 May; 17(5):e13152. PubMed ID: 37246149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.
    Wyrzucki A; Dreyfus C; Kohler I; Steck M; Wilson IA; Hangartner L
    J Virol; 2014 Jun; 88(12):7083-92. PubMed ID: 24719426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Immune Response towards Generation of Universal Anti-HA-Stalk Antibodies after Immunization of Broiler Hens with Triple H5N1/NA-HA-M1 VLPs.
    Gromadzka B; Chraniuk M; Hovhannisyan L; Uranowska K; Szewczyk B; Narajczyk M; Panasiuk M
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broadly neutralizing antibodies to combat influenza virus infection.
    Sun X; Ma H; Wang X; Bao Z; Tang S; Yi C; Sun B
    Antiviral Res; 2024 Jan; 221():105785. PubMed ID: 38145757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
    Zost SJ; Wu NC; Hensley SE; Wilson IA
    J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
    J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation and characterization of monoclonal antibodies against the hemagglutinin of H3N2 influenza A viruses.
    Yang F; Zhu L; Liu F; Cheng L; Yao H; Wu N; Wu H; Li L
    Virus Res; 2022 Aug; 317():198815. PubMed ID: 35595011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divergent Requirement of Fc-Fcγ Receptor Interactions for
    Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses.
    Boonsathorn N; Panthong S; Koksunan S; Chittaganpitch M; Phuygun S; Waicharoen S; Prachasupap A; Sasaki T; Kubota-Koketsu R; Yasugi M; Ono K; Arai Y; Kurosu T; Sawanpanyalert P; Ikuta K; Watanabe Y
    Biochem Biophys Res Commun; 2014 Sep; 452(3):865-70. PubMed ID: 25204499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.
    Srivastava V; Yang Z; Hung IF; Xu J; Zheng B; Zhang MY
    J Virol; 2013 May; 87(10):5831-40. PubMed ID: 23487456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.
    Nagashima K; Dzimianski JV; Han J; Abbadi N; Gingerich AD; Royer F; O'Rourke S; Sautto GA; Ross TM; Ward AB; DuBois RM; Mousa JJ
    J Immunol; 2022 Jul; 209(1):5-15. PubMed ID: 35697384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.